Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

131-metaiodobenzylguanedine therapy of neuroblastoma in childhood

One year of therapeutic experience

  • 26 Accesses

  • 16 Citations

Abstract

Eleven children with neuroblastoma refractory to conventional therapy or relapse of neuroblastoma were treated with 131-metaiodobenzylguanedine (MIBG). The therapeutic results and the side effects were evaluated. In one patient with disseminated bone marrow involvement complete remission was obtained. Partial remission was observed in six patients and stable disease in another. Three patients did not respond to MIBG, in two of them the tumours did not accumulate a sufficient MIBG dose. Clinical and laboratory examinations revealed an excellent tolerance of MIBG in all patients. First attempts to continue cytostasis after MIBG therapy were made. MIBG has a good therapeutic efficacy is sufficiently incorporated into the tumour cell.

This is a preview of subscription content, log in to check access.

Abbreviations

MIBG:

131-I-metaiodobenzylguanedine

CR:

complete remission

PR:

partial remission

LDH:

lactate dehydrogenase

ASAT:

aspartate-amino transferase

ALAT:

alanine-amino transferase

Y-GT:

gamma-glutamyl transpeptidase

AP:

alkaline phosphatase

References

  1. 1.

    Berthold F, Lampert F (1982) Neuroblastomstudie NBL 82 der GPO. Gießen, Studienprotokoll

  2. 2.

    Evans AE, D'Angio GJ, Randolph IG (1971) A proposed staging for children with neuroblastoma. Cancer 27:374–378

  3. 3.

    Feine U, Treuner J, Niethammer D, Meinke J, Müller-Schauenburg W, Klingebiel T, Kaiser W (1985) Neuroblastoma therapy using 131-MIBG: practical experience, observations, and deduction in a series of 20 treamments in 6 children. Eur Nucl Med Congress, London, Abstracts, p 73

  4. 4.

    Kimming B, Brandeis E, Eisenhut M, Bubeck B, Hermann HJ, Zum Winkel K (1983) Szintigraphische Darstellung eines Neuroblastoms. Nuc Compact 14:347

  5. 5.

    Klingebiel TH, Treuner J, Niethammer D, Feine U, Müller-Schauenburg W, Meinke J (1985) Erste Ergebnisse der Behandlung des disseminierten Neuroblastoms mit 131 J-MIBG. Vortrag, gehalten bei der 81. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde in Frankfurt. (Abstract) Monatsschr Kinderheilkd 133:576

  6. 6.

    Manegold K, Maul FD, Baum RP, Happ J, Schwabe D, Klinter D, Gerein V, Kornhuber B, Hör G (1985) Jod-131-IBG-Behandlung des Neuroblastoms: Berechnung der Dosis unter Therapie. Vortrag gehalten bei der 81. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde in Frankfurt. (Abstract) Monatsschr Kinderheilkd 133:577

  7. 7.

    McDougall IR (1984) Malignant pheochromocytoma treated by I-131-MIBG. J Nucl Med 25:249–251

  8. 8.

    Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH, Thompson NW (1981) Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12–17

  9. 9.

    Wieland DM, Wu JL, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with (131J) Jodobenzylguanedine. J Nucl Med 21:349–353

Download references

Author information

Correspondence to D. Schwabe.

Additional information

Dedicated to Prof. O. Hövels on the occasion of his 65th birthday

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schwabe, D., Sahm, S., Gerein, V. et al. 131-metaiodobenzylguanedine therapy of neuroblastoma in childhood. Eur J Pediatr 146, 246–250 (1987). https://doi.org/10.1007/BF00716467

Download citation

Key words

  • Neuroblastoma
  • 131-metaiodobenzylguanedine treatment
  • Therapeutic effect
  • Tolerance